Global G-CSF and G-CSF Biosimilars Market Research Report 2022

G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation.
Due to the COVID-19 pandemic, the global G-CSF and G-CSF Biosimilars market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe G-CSF and G-CSF Biosimilars market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe G-CSF and G-CSF Biosimilars landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Blood Disorders accounting for % of the G-CSF and G-CSF Biosimilars global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Human Growth Hormone segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of G-CSF and G-CSF Biosimilars include Pfizer, Novartis, Roche, Merck & Co., Sanofi, Johnson & Johnson, Gilead Science, GlaxoSmithKline and AbbVie, etc. In terms of revenue, the global 3 largest players have a % market share of G-CSF and G-CSF Biosimilars in 2021.
This report focuses on G-CSF and G-CSF Biosimilars volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall G-CSF and G-CSF Biosimilars market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global G-CSF and G-CSF Biosimilars Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Segment by Application
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer